Erectile Dysfunction Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Erectile dysfunction (ED) is defined as the persistent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance. It affects an estimated 150–200 million men worldwide, with prevalence increasing significantly with age: approximately 40% of men at age 40 and 70% by age 70 have some degree of ED. The aetiology is multifactorial, encompassing vascular (most common, due to endothelial dysfunction and atherosclerosis), neurogenic, hormonal, structural, and psychogenic causes, which frequently coexist.

Treatment of ED is stratified according to aetiology, severity, patient preference, and response to less invasive measures. First-line management consists of lifestyle modification and oral phosphodiesterase type-5 (PDE5) inhibitors, which restore erections in 70–80% of men with adequate sexual stimulation. Second-line therapies include intraurethral and intracavernous vasoactive drug injections, and vacuum erection devices. Surgical penile prosthesis implantation is the definitive third-line treatment for men who fail or cannot use medical therapies.

A thorough evaluation includes medical history to identify reversible risk factors (hypertension, diabetes, hyperlipidaemia, obesity, smoking, and medications such as antihypertensives and antidepressants), physical examination, fasting glucose and testosterone levels, and psychological assessment. ED may be the first manifestation of systemic cardiovascular disease, as penile arteries are smaller than coronary arteries and atherosclerosis manifests there earlier—making ED a significant marker for increased cardiovascular risk.

ED treatment addresses the primary presenting symptom of inability to achieve or maintain erections, but the underlying aetiologies vary considerably and drive treatment selection. Vasculogenic ED from arterial insufficiency or venous leak responds best to oral PDE5 inhibitors and, when severe, to penile revascularisation or prosthesis implantation. Neurogenic ED—from diabetic neuropathy, multiple sclerosis, Parkinson's disease, or radical prostatectomy—benefits from PDE5 inhibitors and penile rehabilitation programmes using regular vacuum device or PDE5 inhibitor use post-surgery to preserve erectile tissue.

Hypogonadism (testosterone deficiency) causing ED responds to testosterone replacement therapy, which restores sexual desire and may improve response to PDE5 inhibitors. Psychogenic ED—from performance anxiety, depression, or relationship issues—benefits from cognitive-behavioural sex therapy, sometimes combined with short-term use of PDE5 inhibitors to rebuild confidence. Peyronie's disease (penile fibrosis causing curvature and ED) is treated with collagenase clostridium histolyticum injections, penile traction therapy, and surgery in severe cases. Post-radical prostatectomy and post-radiotherapy ED for prostate cancer are common indications for penile rehabilitation and prosthetic surgery.

Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are appropriate first-line therapy for the vast majority of men with ED, irrespective of aetiology, provided there are no contraindications. They are safe in most men including those with controlled hypertension, diabetes, and cardiovascular disease. Ideal candidates for penile prosthesis implantation are men with severe ED who have failed or cannot tolerate oral pharmacotherapy and are motivated for a surgical solution, including those with radical prostatectomy, Peyronie's disease with ED, priapism-related damage, and penile vascular failure.

Contraindications to PDE5 inhibitors include concurrent use of nitrate medications (absolute contraindication due to severe hypotension), recent myocardial infarction within 6 months, severe cardiac failure, and hypotension. Alpha-blocker use requires dose separation and is a relative caution. Testosterone replacement is contraindicated in men with prostate cancer or elevated PSA without urological review, and in those with polycythaemia. Penile prosthesis surgery requires standard surgical fitness and carries risks of infection, which must be balanced against the quality-of-life gain.

PDE5 inhibitors work by enhancing nitric oxide-mediated smooth muscle relaxation in the corpus cavernosum in response to sexual stimulation, increasing blood flow and facilitating erection. Sildenafil (Viagra) is taken 30–60 minutes before intercourse and lasts 4–6 hours. Tadalafil (Cialis) has a 36-hour duration and is also available as a daily low-dose (5 mg) formulation for convenience. Avanafil has the fastest onset (~15 minutes). All require sexual stimulation to be effective.

Second-line therapies include intracavernous injections (alprostadil alone or in combination with phentolamine and papaverine—'trimix') injected directly into the corpus cavernosum, producing erections within 5–15 minutes regardless of psychological state. Intraurethral alprostadil (MUSE) is a less invasive alternative with lower efficacy. Vacuum erection devices use negative pressure to draw blood into the penis, with a constriction ring applied to maintain the erection. Surgical penile prosthesis implantation—either a malleable (semi-rigid) or inflatable three-piece device—provides reliable, on-demand erections with the highest patient and partner satisfaction rates (>90%). Low-intensity shockwave therapy (LiSWT) is an emerging non-invasive treatment promoting angiogenesis in vasculogenic ED with emerging evidence of benefit. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

PDE5 inhibitors achieve satisfactory erections in approximately 70–80% of men across all aetiologies, rising to over 80% in psychogenic ED and lower in post-radical prostatectomy ED where nerve-sparing was not performed. Tadalafil daily dosing has shown improvement in urinary symptoms from benign prostatic hyperplasia alongside ED in clinical trials. Treatment of underlying cardiovascular risk factors—hypertension, diabetes, dyslipidaemia, and cessation of smoking—independently improves erectile function and is essential alongside pharmacotherapy.

Penile prosthesis implantation provides reliable functional erections in virtually all implanted men, with partner satisfaction rates of 88–96% in published series. The AMS 700cx and Coloplast Titan three-piece inflatable devices have 5-year mechanical survival rates exceeding 90%. Men who undergo implantation report the highest treatment satisfaction scores of any ED therapy modality in comparative studies. Recovery of spontaneous erectile function is not expected after implant surgery, but the prosthesis provides a definitive solution for refractory ED.

PDE5 inhibitor side effects include headache (15%), flushing (11%), dyspepsia, nasal congestion, and visual colour disturbances (rare, with sildenafil). Priapism—prolonged erection exceeding 4 hours—is a rare emergency (less than 1%) requiring immediate medical attention to prevent permanent vascular damage. Sudden hearing loss and non-arteritic anterior ischaemic optic neuropathy (NAION) are rare associations that have been reported with PDE5 inhibitors.

Intracavernous injection complications include bruising, prolonged erection (5–10%), pain at injection site, and with long-term use, corporal fibrosis. Vacuum device complications include penile discomfort, bruising, and inability to ejaculate in some patients. Penile prosthesis surgical risks include infection (1–3% overall, higher in diabetics—up to 5%), mechanical failure, device erosion or extrusion (less than 2%), and, rarely, injury to the urethra or neurovascular bundle. Antibiotic-impregnated prostheses (InhibiZone) have significantly reduced infection rates in modern series. Once infected, prosthetic removal is required.

For men on oral PDE5 inhibitors, initial follow-up at 4–8 weeks assesses treatment response and tolerability. Dose optimisation is important—many treatment failures result from inadequate dosing or incorrect timing of administration. Failure of one PDE5 inhibitor does not preclude response to another. Annual review should address underlying cardiovascular risk factor control and testosterone levels. Men with ED should be screened for depression, which both causes and results from sexual dysfunction.

After penile prosthesis implantation, the device is typically not activated for 4–6 weeks to allow healing. The prosthesis is inflated by the patient for the first time under urologist supervision and checked for correct function. Patients are instructed in device cycling (daily inflation for 15 minutes) during the healing period to optimise tissue expansion around the cylinders. Sexual activity can be resumed at 6–8 weeks post-implant. Annual follow-up assesses device function and patient satisfaction; early mechanical concerns should be reported to allow timely revision before erosion occurs.

Brand-name PDE5 inhibitors cost USD 25–80 per tablet in the United States without insurance, though generic sildenafil and tadalafil are available for USD 1–5 per tablet, making oral medical therapy highly affordable globally. In the UK, generic sildenafil is available over-the-counter at approximately GBP 2–5 per tablet. Penile prosthesis surgery in the US costs USD 15,000–30,000 including the device and hospital charges; the device alone (AMS 700) costs approximately USD 6,000–10,000. Low-intensity shockwave therapy costs USD 3,000–6,000 for a full treatment course in the US.

In India, penile prosthesis implantation is available at leading urology centres for USD 5,000–10,000, representing 60–70% savings. Thailand and Malaysia offer comparable procedures at USD 7,000–12,000. A 3-piece inflatable device surgery at a reputable urology centre in India or Thailand uses identical FDA/CE-approved prosthetic devices as Western centres. Patients travelling for penile implant surgery should allow 5–7 days for the procedure and immediate recovery, with follow-up instructions for managing device activation on return home.

Lifestyle modification—including exercise (aerobic training for 30 minutes 4 times per week improves ED scores by 50%), weight loss, smoking cessation, alcohol reduction, and optimisation of diabetes and hypertension—is the most sustainable long-term approach for vasculogenic ED and can restore spontaneous erectile function in mild to moderate disease. A randomised trial demonstrated that aerobic exercise alone improves erectile function comparably to sildenafil in men with vasculogenic ED.

Psychosexual therapy (sex therapy, cognitive-behavioural therapy, mindfulness-based approaches) is effective for psychogenic and mixed-aetiology ED, particularly when performance anxiety or relationship issues are prominent. It may be used alone or combined with short-term PDE5 inhibitor use to rebuild confidence. Penile revascularisation surgery—microsurgical bypass of obstructed penile arteries—is occasionally offered to young men with isolated arteriogenic ED (typically post-perineal or pelvic trauma) as a potentially curative surgical option, with success rates of 50–70% in carefully selected cases.